Hyperglycosylated analog of human erythropoietin, q.v., produced by recombinant DNA technology. mol wt ≈38 kDa. Engineered to contain 2 extra carbohydrate addition sites, leading to increased circulating half-life. Prepn: S. G. Elliott, T. E. Byrne, WO 9505465 (1995 to Amgen). Review of development and pharmacology: I. C. Macdougall, Semin. Nephrol. 20, 375-381 (2000); of clinical experience in treatment of anemia of kidney disease: A. R. Nissenson, Am. J. Kidney Dis. 38, 1390-1397 (2001); of chemotherapy induced anemia: J. Vansteenkiste, I. Wauters, Expert Opin. Pharmacother. 6, 429-440 (2005). Series of articles on clinical experience in cancer-related anemia: Br. J. Cancer 84, Suppl. 1, 1-38 (2001).
Hematopoietic.
Hematopoietic